Results 201 to 210 of about 4,657 (257)

Decreased ATF5 level contributes to improved mitochondrial function in oocytes exposed to vitrification stress. [PDF]

Front Cell Dev Biol
Zhou G, Liu A, Bai J, Liu H, Zhu Y, Luo Y, Zheng L, Hou Y, Li J, Fu X.   +9 more
europepmc   +1 more source

Roflumilast inhibits tumor growth and migration in STK11/LKB1 deficient pancreatic cancer. [PDF]

Cell Death Discov
Zhang S, Yun D, Yang H, Eckstein M, Elbait GD, Zhou Y, Lu Y, Yang H, Zhang J, Dörflein I, Britzen-Laurent N, Pfeffer S, Stemmler MP, Dahl A, Mukhopadhyay D, Chang D, He H, Zeng S, Lan B, Frey B, Hampel C, Lentsch E, Gollavilli PN, Büttner C, Ekici AB, Biankin A, Schneider-Stock R, Ceppi P, Grützmann R, Pilarsky C.   +29 more
europepmc   +1 more source

Exploring the Genetic Landscape of Chorea in Infancy and Early Childhood: Implications for Diagnosis and Treatment. [PDF]

Curr Issues Mol Biol
Spoto G, Ceraolo G, Butera A, Di Rosa G, Nicotera AG.   +4 more
europepmc   +1 more source

Altered huntingtin-chromatin interactions predict transcriptional and epigenetic changes in Huntington's disease.

Dis Model Mech
Pearl JR, Shetty AC, Cantle JP, Bergey DE, Bragg RM, Coffey SR, Kordasiewicz HB, Hood LE, Price ND, Ament SA, Carroll JB.   +10 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Emerging Biology of PDE10A

Current Pharmaceutical Design, 2014
Cyclic AMP and cyclic GMP are essential second messengers that regulate multiple signaling pathways in virtually all cell types. Their accumulation in cells is finely regulated by cyclic nucleotide phosphodiesterases (PDEs), the only enzymes that can degrade these signaling molecules and thus provide exquisite control over intracellular signaling ...
Lindsay S. Wilson, Nicholas J. Brandon
openaire   +3 more sources

N-Acylhydrazones as inhibitors of PDE10A

Bioorganic & Medicinal Chemistry Letters, 2011
Cyclic nucleotide phosphodiesterases (PDEs) are represented by a large superfamily of enzymes. A series of hydrazone-based inhibitors was synthesized and shown to be novel, potent, and selective against PDE10A. Optimized compounds of this class were efficacious in animal models of schizophrenia and may be useful for the treatment of this disease.
Thomas Neil Wheeler, Vince Florio, Andrew Osnowski, Sasha Gragerov, Derek Johnston, Wendy MacDonald, Harbol Kevin L, Lee Mitchell, Alex Rohde, Neil S. Cutshall, Rene Onrust, Jennifer Lynn Gage, György Dormán, László Ürögdi   +13 more
openaire   +3 more sources